Ovarian Cancer | Specialty

Early Marketing of ROCA CA-125 Ovarian Test Sparks Concern

October 7th 2015

The jury is still out on whether use of an algorithm to help classify risk levels in ovarian cancer can improve overall survival but a company is already marketing the system in Britain and plans to bring it to the United States before the end of the year.

Nivolumab Active in Platinum-Resistant Ovarian Cancer

September 17th 2015

Nivolumab (Opdivo) demonstrated clinical activity and safety in patients with platinum-resistant ovarian cancer.

Birinapant May Reduce Chemoresistance, Recurrence in Certain Ovarian Cancers

September 13th 2015

Sanaz Memarzadeh, MD, PhD, discusses a combination regimen of birinapant and carboplatin in patients with high-grade serous ovarian cancers and high levels of cellular inhibitor of apoptosis protein (cIAP) in their CA-125–negative cells.

Dr. Coleman on Next Steps Following ARIEL2 Trial for Ovarian Cancer

September 11th 2015

Robert L. Coleman, MD, The University of Texas MD Anderson Cancer Center, discusses the next steps following results of the ARIEL2 trial, which aimed to identify patients with ovarian cancer most likely to respond to rucaparib using tumor genetic analysis.

PARP Inhibitors Move Into the Limelight

August 21st 2015

Research evidence has been mounting that PARP inhibitors are not just for gynecologic malignancies-or for patients whose tumors harbor inherited BRCA defects.

Dr. Kauff on Challenges in Treating Uterine Cancer

August 19th 2015

Noah D. Kauff, MD, FACOG, gynecologist and geneticist, director, Ovarian Cancer Screening and Prevention, Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, discusses the main challenges in treating uterine cancer.

Lead Researcher Discusses Anti-PD-L1 Agent Avelumab in Ovarian Cancer

August 18th 2015

Jeffrey R. Infante, MD, discusses the fully human PD-L1 IgG1 antibody avelumab, which demonstrated clinical activity in patients with previously treated, recurrent/refractory ovarian cancer in a phase Ib open-label expansion trial.

Intraperitoneal Chemotherapy Uptake Sluggish in Ovarian Cancer

August 11th 2015

Frontline treatment with intraperitoneal chemotherapy is commonly underutilized for a majority of patients with optimally cytoreduced stage III ovarian cancer, despite recommendations for its use and a clear demonstration of improved overall survival.

Novel Immunotherapeutic Agent Shows Benefit in Ovarian Cancer

August 10th 2015

Premal H. Thaker, MD, discusses EGEN-001 in combination with pegylated liposomal doxorubicin and the potential of immunotherapy agents in ovarian and other similar cancers.

Dr. Thaker on EGEN-001 Combined With Doxorubicin for Ovarian Cancer

July 28th 2015

Premal H. Thaker, MD, MS, discusses a phase I study examining the combination of EGEN-001 and doxorubicin for the treatment of patients with platinum-resistant ovarian cancer.

Failure to Follow Weight-Based Chemo Guidelines Lowers Survival in Ovarian Cancer

July 23rd 2015

Women with ovarian cancer who experienced an average dose reduction of ≤85% had a 35% higher mortality risk than those who received normal dosing.

Dr. Infante on Avelumab's Potential in Ovarian Cancer

July 22nd 2015

Jeffrey R. Infante, MD, director, Drug Development Program, Sarah Cannon Research Institute, discusses the potential impact avelumab could have on the treatment of patients with ovarian cancer.

Coleman Explains New Biomarker for PARP Inhibitors in Ovarian Cancer

July 17th 2015

Robert Coleman, MD, discusses a potential new biomarker for PARP inhibition in ovarian cancer that was examined in the ARIEL2 trial.

FDA Grants Peptide Vaccine Orphan Status for Ovarian Cancer

July 17th 2015

The FDA has granted an orphan drug designation to the immunotherapy DPX-Survivac as a treatment for women with ovarian cancer.

Future of Ovarian and Cervical Cancers

July 2nd 2015

Treating Locally Advanced Cervical Cancer

July 2nd 2015

Prevention and Early Detection of Cervical Cancer

July 2nd 2015

Carboplatin Versus Cisplatin in Cervical Cancer

July 2nd 2015

Bevacizumab in Advanced Cervical Cancer

July 2nd 2015

Managing Platinum-Resistant Ovarian Cancer

July 2nd 2015